{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:12:07Z","timestamp":1790302327336,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019125","name":"Sorbonne Universit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"name":"New French Atherosclerosis Society"},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007241","name":"Universit\u00e9 Paris-Saclay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CE44-0006-03"],"award-info":[{"award-number":["ANR-23-CE44-0006-03"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CE44-0006-03"],"award-info":[{"award-number":["ANR-23-CE44-0006-03"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CE44-0006-03"],"award-info":[{"award-number":["ANR-23-CE44-0006-03"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Sphingosine 1-phosphate (S1P) is a key mediator of lipid signaling with strong immunomodulatory and anti-inflammatory effects. Circulating S1P levels including S1P in high-density lipoproteins (HDL) were demonstrated to be inversely associated with cardiovascular diseases (CVD). However, no studies are available regarding a potential implication of S1P on the risk of CVD in type 2 diabetes (T2D). The objective of this study is to determine if the increased CVD risk in T2D may involve an alteration of circulating S1P species as well as their precursors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 168 and 31 patients with T2D (154 men and 45 women) with available Coronary artery calcification (CAC) score from the DIACART and CERABIAB cohorts, respectively, were included in the study. Quantification of S1P species and their precursors was carried out by LC\u2013MS\/MS in plasma and isolated HDL. CAC score was modeled as a binary variable (0\/1 below or equal\/above 100) using CAC\u2009&lt;\u2009100 for reference. S1P species or precursors were modeled as binary variables dichotomized at the median (0\/1: below or equal\/above the median). The relationships between S1P species and CAC score modeled as a binary variable (below or equal\/above 100) was evaluated by linear regression analyses. In vitro experiments were conducted to evaluate the contribution of HDL-S1P content on anti-inflammatory properties of HDL particles.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Multivariate analysis revealed that plasma S1P levels, especially d18:1-S1P, and sphingosine in HDL were inversely associated with the high risk of CVD (CAC\u2009&gt;\u2009100) in patients with T2D. Clustering of HDL according to their concentration in S1P species and their precursors revealed that S1P-impoverished HDL is a major feature of patients with a CAC\u2009&gt;\u2009100. In vitro analysis of monocyte adhesion and inflammation in human umbilical vein endothelial cells as well as inflammatory phenotype of human macrophages demonstrated that low HDL-S1P exhibited impaired anti-inflammatory properties in comparison to high HDL-S1P.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study unraveled that circulating S1P and their precursors are biomarkers of coronary atherosclerosis in T2D, which may underlie the lower abundance of S1P and anti-inflammatory activities of HDL.<\/jats:p>\n            <jats:p>\n              <jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov number, NCT02431234.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s12933-025-02624-9","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:32:02Z","timestamp":1740155522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Inverse relationship between circulating sphingosine-1-phosphate and precursor species and coronary artery calcification score in type 2 diabetes"],"prefix":"10.1186","volume":"24","author":[{"given":"Wilfried","family":"Le Goff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bourron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Materne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Galier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tan-Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Guillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Hartemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Redheuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Foufelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Le Stunff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hajduch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"2624_CR1","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/dme.13296","volume":"34","author":"A Khan","year":"2017","unstructured":"Khan A, Petropoulos IN, Ponirakis G, Malik RA. Visual complications in diabetes mellitus: beyond retinopathy. Diabet Med J Br Diabet Assoc. 2017;34:478\u201384.","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"2624_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17:83.","journal-title":"Cardiovasc Diabetol"},{"key":"2624_CR3","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/ijms21051835","volume":"21","author":"A Poznyak","year":"2020","unstructured":"Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21:1835.","journal-title":"Int J Mol Sci"},{"key":"2624_CR4","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","volume":"47","author":"E Falk","year":"2006","unstructured":"Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47:C7-12.","journal-title":"J Am Coll Cardiol"},{"key":"2624_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/metabo11120807","volume":"11","author":"I Bonilha","year":"2021","unstructured":"Bonilha I, Hajduch E, Luchiari B, Nadruz W, Le Goff W, Sposito AC. The reciprocal relationship between LDL metabolism and type 2 diabetes mellitus. Metabolites. 2021;11:807.","journal-title":"Metabolites"},{"key":"2624_CR6","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00125-021-05509-0","volume":"64","author":"E Xepapadaki","year":"2021","unstructured":"Xepapadaki E, Nikdima I, Sagiadinou EC, Zvintzou E, Kypreos KE. HDL and type 2 diabetes: the chicken or the egg? Diabetologia. 2021;64:1917\u201326.","journal-title":"Diabetologia"},{"key":"2624_CR7","first-page":"2432","volume":"77","author":"W Annema","year":"2013","unstructured":"Annema W, von Eckardstein A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ J Off J Jpn Circ Soc. 2013;77:2432\u201348.","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"2624_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2021.159072","volume":"1867","author":"WS Davidson","year":"2022","unstructured":"Davidson WS, Shah AS, Sexmith H, Gordon SM. The HDL proteome watch: compilation of studies leads to new insights on HDL function. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867: 159072.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2624_CR9","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1161\/ATVBAHA.113.301468","volume":"33","author":"L Camont","year":"2013","unstructured":"Camont L, Lhomme M, Rached F, Le Goff W, N\u00e8gre-Salvayre A, Salvayre R, Calzada C, Lagarde M, Chapman MJ, Kontush A. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol. 2013;33:2715\u201323.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2624_CR10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1161\/ATVBAHA.120.305565","volume":"41","author":"E Engelbrecht","year":"2021","unstructured":"Engelbrecht E, MacRae CA, Hla T. Lysolipids in vascular development, biology, and disease. Arterioscler Thromb Vasc Biol. 2021;41:564\u201384.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2624_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1126\/science.1139221","volume":"316","author":"R Pappu","year":"2007","unstructured":"Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng Y-W, Huang Y, Cyster JG, Coughlin SR. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316:295\u20138.","journal-title":"Science"},{"key":"2624_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/CIRCRESAHA.107.165845","volume":"102","author":"K Venkataraman","year":"2008","unstructured":"Venkataraman K, Lee Y-M, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C, Hla T. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res. 2008;102:669\u201376.","journal-title":"Circ Res"},{"key":"2624_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fphar.2015.00243","volume":"6","author":"B Levkau","year":"2015","unstructured":"Levkau B. HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications. Front Pharmacol. 2015;6:243.","journal-title":"Front Pharmacol"},{"key":"2624_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000362990","volume":"34","author":"S Fayyaz","year":"2014","unstructured":"Fayyaz S, Japtok L, Kleuser B. Divergent role of sphingosine 1-phosphate on insulin resistance. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2014;34:134\u201347.","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"issue":"Pt 3","key":"2624_CR15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1042\/bj3520809","volume":"352","author":"N Murata","year":"2000","unstructured":"Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, Ui M, Okajima F. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000;352(Pt 3):809\u201315.","journal-title":"Biochem J"},{"key":"2624_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MOL.0000000000000825","volume":"33","author":"P Therond","year":"2022","unstructured":"Therond P, Chapman MJ. Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment. Curr Opin Lipidol. 2022;33:199\u2013207.","journal-title":"Curr Opin Lipidol"},{"key":"2624_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1172\/JCI200418004","volume":"113","author":"J-R Nofer","year":"2004","unstructured":"Nofer J-R, van der Giet M, T\u00f6lle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, G\u00f6decke A, Ishii I, Kleuser B, Sch\u00e4fers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113:569\u201381.","journal-title":"J Clin Invest"},{"key":"2624_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cellsig.2005.07.011","volume":"18","author":"T Kimura","year":"2006","unstructured":"Kimura T, Tomura H, Mogi C, Kuwabara A, Ishiwara M, Shibasawa K, Sato K, Ohwada S, Im D-S, Kurose H, Ishizuka T, Murakami M, Okajima F. Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells. Cell Signal. 2006;18:841\u201350.","journal-title":"Cell Signal"},{"key":"2624_CR19","doi-asserted-by":"publisher","first-page":"9613","DOI":"10.1073\/pnas.1103187108","volume":"108","author":"C Christoffersen","year":"2011","unstructured":"Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstr\u00f6m J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlb\u00e4ck B. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA. 2011;108:9613\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2624_CR20","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1194\/jlr.P089409","volume":"60","author":"M Liu","year":"2019","unstructured":"Liu M, Frej C, Langefeld CD, Divers J, Bowden DW, Carr JJ, Gebre AK, Xu J, Larsson B, Dahlb\u00e4ck B, Freedman BI, Parks JS. Plasma apoM and S1P levels are inversely associated with mortality in African Americans with type 2 diabetes mellitus. J Lipid Res. 2019;60:1425\u201331.","journal-title":"J Lipid Res"},{"key":"2624_CR21","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/cells9071682","volume":"9","author":"J Guitton","year":"2020","unstructured":"Guitton J, Bandet CL, Mariko ML, Tan-Chen S, Bourron O, Benomar Y, Hajduch E, Le Stunff H. Sphingosine-1-phosphate metabolism in the regulation of obesity\/type 2 diabetes. Cells. 2020;9:1682.","journal-title":"Cells"},{"key":"2624_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00018-018-2984-8","volume":"76","author":"RR Magaye","year":"2019","unstructured":"Magaye RR, Savira F, Hua Y, Kelly DJ, Reid C, Flynn B, Liew D, Wang BH. The role of dihydrosphingolipids in disease. Cell Mol Life Sci CMLS. 2019;76:1107\u201334.","journal-title":"Cell Mol Life Sci CMLS"},{"key":"2624_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrm2329","volume":"9","author":"YA Hannun","year":"2008","unstructured":"Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139\u201350.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2624_CR24","doi-asserted-by":"publisher","first-page":"26322","DOI":"10.1074\/jbc.M109.023192","volume":"284","author":"T Hornemann","year":"2009","unstructured":"Hornemann T, Penno A, R\u00fctti MF, Ernst D, Kivrak-Pfiffner F, Rohrer L, von Eckardstein A. The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases. J Biol Chem. 2009;284:26322\u201330.","journal-title":"J Biol Chem"},{"key":"2624_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0021-9258(17)49922-4","volume":"295","author":"W Wang","year":"2020","unstructured":"Wang W, Xiang P, Chew WS, Torta F, Bandla A, Lopez V, Seow WL, Lam BWS, Chang JK, Wong P, Chayaburakul K, Ong W-Y, Wenk MR, Sundar R, Herr DR. Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. J Biol Chem. 2020;295:1143\u201352.","journal-title":"J Biol Chem"},{"key":"2624_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.atherosclerosis.2015.05.037","volume":"241","author":"I Sutter","year":"2015","unstructured":"Sutter I, Velagapudi S, Othman A, Riwanto M, Manz J, Rohrer L, Rentsch K, Hornemann T, Landmesser U, von Eckardstein A. Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis. 2015;241:539\u201346.","journal-title":"Atherosclerosis"},{"key":"2624_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0002-8703(03)00118-2","volume":"146","author":"DH Deutschman","year":"2003","unstructured":"Deutschman DH, Carstens JS, Klepper RL, Smith WS, Page MT, Young TR, Gleason LA, Nakajima N, Sabbadini RA. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J. 2003;146:62\u20138.","journal-title":"Am Heart J"},{"key":"2624_CR28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00395-010-0112-5","volume":"105","author":"KJE Sattler","year":"2010","unstructured":"Sattler KJE, Elbasan \u015e, Keul P, Elter-Schulz M, Bode C, Gr\u00e4ler MH, Br\u00f6cker-Preuss M, Budde T, Erbel R, Heusch G, Levkau B. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol. 2010;105:821\u201332.","journal-title":"Basic Res Cardiol"},{"key":"2624_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1476-511X-10-70","volume":"10","author":"KM Argraves","year":"2011","unstructured":"Argraves KM, Sethi AA, Gazzolo PJ, Wilkerson BA, Remaley AT, Tybjaerg-Hansen A, Nordestgaard BG, Yeatts SD, Nicholas KS, Barth JL, Argraves W. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011;10:70.","journal-title":"Lipids Health Dis"},{"key":"2624_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2015.03.011","volume":"240","author":"A Othman","year":"2015","unstructured":"Othman A, Saely CH, Muendlein A, Vonbank A, Drexel H, Von Eckardstein A, Hornemann T. Plasma C20-Sphingolipids predict cardiovascular events independently from conventional cardiovascular risk factors in patients undergoing coronary angiography. Atherosclerosis. 2015;240:216\u201321.","journal-title":"Atherosclerosis"},{"key":"2624_CR31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2337\/db19-0811","volume":"69","author":"M Kurano","year":"2020","unstructured":"Kurano M, Tsukamoto K, Shimizu T, Kassai H, Nakao K, Aiba A, Hara M, Yatomi Y. Protection against insulin resistance by apolipoprotein M\/Sphingosine-1-phosphate. Diabetes. 2020;69:867\u201381.","journal-title":"Diabetes"},{"key":"2624_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192616","volume":"13","author":"T Vaisar","year":"2018","unstructured":"Vaisar T, Couzens E, Hwang A, Russell M, Barlow CE, DeFina LF, Hoofnagle AN, Kim F. Type 2 diabetes is associated with loss of HDL endothelium protective functions. PLoS ONE. 2018;13: e0192616.","journal-title":"PLoS ONE"},{"key":"2624_CR33","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/ATVBAHA.115.307049","volume":"36","author":"JW Brinck","year":"2016","unstructured":"Brinck JW, Thomas A, Lauer E, Jornayvaz FR, Brulhart-Meynet M-C, Prost J-C, Pataky Z, L\u00f6fgren P, Hoffstedt J, Eriksson M, Pramfalk C, Morel S, Kwak BR, Van Eck M, James RW, Frias MA. Diabetes mellitus is associated with reduced high-density lipoprotein sphingosine-1-phosphate content and impaired high-density lipoprotein cardiac cell protection. Arterioscler Thromb Vasc Biol. 2016;36:817\u201324.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2624_CR34","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/archinte.164.12.1285","volume":"164","author":"MJ Pletcher","year":"2004","unstructured":"Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the Coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med. 2004;164:1285.","journal-title":"Arch Intern Med"},{"key":"2624_CR35","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1210\/jc.2014-1047","volume":"99","author":"O Bourron","year":"2014","unstructured":"Bourron O, Aubert CE, Liabeuf S, Cluzel P, Lajat-Kiss F, Dadon M, Komajda M, Mentaverri R, Brazier M, Pierucci A, Morel F, Jacqueminet S, Massy ZA, Hartemann A. Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor \u03baB ligand, osteoprotegerin, and neuropathy. J Clin Endocrinol Metab. 2014;99:4250\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"2624_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100154","volume":"1","author":"A Carlier","year":"2020","unstructured":"Carlier A, Phan F, Szpigel A, Hajduch E, Salem J-E, Gautheron J, Le Goff W, Gu\u00e9rin M, Lachkar F, Ratziu V, Hartemann A, Ferr\u00e9 P, Foufelle F, Bourron O. Dihydroceramides in triglyceride-enriched VLDL are associated with nonalcoholic fatty liver disease severity in type 2 diabetes. Cell Rep Med. 2020;1: 100154.","journal-title":"Cell Rep Med"},{"key":"2624_CR37","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jacl.2017.03.016","volume":"11","author":"A Gallo","year":"2017","unstructured":"Gallo A, Giral P, Carri\u00e9 A, Carreau V, B\u00e9liard S, Bittar R, Maranghi M, Arca M, Cluzel P, Redheuil A, Bruckert E, Rosenbaum D. Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11:704-711.e2.","journal-title":"J Clin Lipidol"},{"key":"2624_CR38","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0735-1097(90)90282-T","volume":"15","author":"AS Agatston","year":"1990","unstructured":"Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2624_CR39","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.atherosclerosis.2015.06.040","volume":"241","author":"D Denimal","year":"2015","unstructured":"Denimal D, de Barros JP, Petit JM, Bouillet B, Verg\u00e8s B, Duvillard L. Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration. Atherosclerosis. 2015;241(2):752\u201360.","journal-title":"Atherosclerosis"},{"key":"2624_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ymeth.2006.05.004","volume":"39","author":"J Bielawski","year":"2006","unstructured":"Bielawski J, Szulc ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods. 2006;39:82\u201391.","journal-title":"Methods"},{"key":"2624_CR41","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1161\/ATVBAHA.109.194548","volume":"29","author":"S Larrede","year":"2009","unstructured":"Larrede S, Quinn CM, Jessup W, Frisdal E, Olivier M, Hsieh V, Kim M-J, Eck MV, Couvert P, Carrie A, Giral P, Chapman MJ, Guerin M, Goff WL. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages Is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol. 2009;29:1930\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2624_CR42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2144\/btn-2019-0169","volume":"68","author":"V Vincent","year":"2020","unstructured":"Vincent V, Thakkar H, Verma A, Sen A, Chandran N, Singh A. A novel flow cytometry-based quantitative monocyte adhesion assay to estimate endothelial cell activation in vitro. Biotechniques. 2020;68:325\u201333.","journal-title":"Biotechniques"},{"key":"2624_CR43","doi-asserted-by":"publisher","first-page":"e0168302","DOI":"10.1371\/journal.pone.0168302","volume":"11","author":"I Soltau","year":"2016","unstructured":"Soltau I, Mudersbach E, Geissen M, Schwedhelm E, Winkler MS, Geffken M, Peine S, Schoen G, Debus ES, Larena-Avellaneda A, Daum G. Serum-sphingosine-1-phosphate concentrations are inversely associated with atherosclerotic diseases in humans. PLoS ONE. 2016;11:e0168302.","journal-title":"PLoS ONE"},{"key":"2624_CR44","doi-asserted-by":"crossref","unstructured":"Denimal D, Benanaya S, Monier S, Simoneau I, Pais de Barros JP, Le Goff W, Bouillet B, Verg\u00e8s B, Duvillard L. Normal HDL cholesterol efflux and anti-inflammatory capacities in type 2 diabetes despite lipidomic abnormalities. J Clin Endocrinol Metabol. 2022;107(9):e3816-23.","DOI":"10.1210\/clinem\/dgac339"},{"key":"2624_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cca.2014.02.026","volume":"433","author":"RPF Dullaart","year":"2014","unstructured":"Dullaart RPF, Annema W, Tio RA, Tietge UJF. The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol. Clin Chim Acta. 2014;433:34\u20138.","journal-title":"Clin Chim Acta"},{"key":"2624_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","volume":"13","author":"RS Rosenson","year":"2016","unstructured":"Rosenson RS, Brewer HB, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13:48\u201360.","journal-title":"Nat Rev Cardiol"},{"key":"2624_CR47","doi-asserted-by":"publisher","first-page":"e131491","DOI":"10.1172\/jci.insight.131491","volume":"5","author":"M Cardner","year":"2020","unstructured":"Cardner M, Yalcinkaya M, Goetze S, Luca E, Balaz M, Hunjadi M, Hartung J, Shemet A, Kr\u00e4nkel N, Radosavljevic S, Keel M, Othman A, Karsai G, Hornemann T, Claassen M, Liebisch G, Carreira E, Ritsch A, Landmesser U, Kr\u00fctzfeldt J, Wolfrum C, Wollscheid B, Beerenwinkel N, Rohrer L, von Eckardstein A. Structure-function relationships of HDL in diabetes and coronary heart disease. JCI Insight. 2020;5:e131491.","journal-title":"JCI Insight"},{"key":"2624_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00395-023-01004-2","volume":"118","author":"I Guillas","year":"2023","unstructured":"Guillas I, Lhomme M, Pionneau C, Matheron L, Ponnaiah M, Galier S, Lebreton S, Delbos M, Ma F, Darabi M, Khoury PE, Abifadel M, Couvert P, Giral P, Lesnik P, Guerin M, Le Goff W, Kontush A. Identification of the specific molecular and functional signatures of pre-beta-HDL: relevance to cardiovascular disease. Basic Res Cardiol. 2023;118:33.","journal-title":"Basic Res Cardiol"},{"key":"2624_CR49","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1161\/CIRCRESAHA.120.317178","volume":"127","author":"Y He","year":"2020","unstructured":"He Y, Ronsein GE, Tang C, Jarvik GP, Davidson WS, Kothari V, Song HD, Segrest JP, Bornfeldt KE, Heinecke JW. Diabetes impairs cellular cholesterol efflux from ABCA1 to small HDL particles. Circ Res. 2020;127:1198\u2013210.","journal-title":"Circ Res"},{"key":"2624_CR50","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1038\/s41467-024-50341-w","volume":"15","author":"M Hering","year":"2024","unstructured":"Hering M, Madi A, Sandhoff R, Ma S, Wu J, Mieg A, Richter K, Mohr K, Knabe N, Stichling D, Poschet G, Bestvater F, Frank L, Utikal J, Umansky V, Cui G. Sphinganine recruits TLR4 adaptors in macrophages and promotes inflammation in murine models of sepsis and melanoma. Nat Commun. 2024;15:6067.","journal-title":"Nat Commun"},{"key":"2624_CR51","doi-asserted-by":"crossref","unstructured":"Izquierdo MC, Shanmugarajah N, Lee SX, Kraakman MJ, Westerterp M, Kitamoto T, Harris M, Cook JR, Gusarova GA, Zhong K, Marbuary E, O-Sullivan I, Rasmus N, Camastra S, Unterman TG, Ferrannini E, Hurwitz BE, Haeusler RA. Hepatic FoxOs link insulin signaling with plasma lipoprotein metabolism through an apolipoprotein M\/sphingosine-1-phosphate pathway. J Clin Invest 2022;132:e146219.","DOI":"10.1172\/JCI146219"},{"key":"2624_CR52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2796.2009.02095.x","volume":"266","author":"P Plomgaard","year":"2009","unstructured":"Plomgaard P, Dullaart RPF, de Vries R, Groen AK, Dahlb\u00e4ck B, Nielsen LB. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects. J Intern Med. 2009;266:258\u201367.","journal-title":"J Intern Med"},{"key":"2624_CR53","doi-asserted-by":"publisher","first-page":"730","DOI":"10.5551\/jat.55699","volume":"28","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Kurano M, Nanya M, Shimizu T, Ohkawa R, Tozuka M, Yatomi Y. Glycation of HDL polymerizes apolipoprotein M and attenuates its capacity to bind to sphingosine 1-phosphate. J Atheroscler Thromb. 2021;28:730\u201341.","journal-title":"J Atheroscler Thromb"},{"key":"2624_CR54","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S1388-1981(02)00147-6","volume":"1582","author":"F Okajima","year":"2002","unstructured":"Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta. 2002;1582:132\u20137.","journal-title":"Biochim Biophys Acta"},{"key":"2624_CR55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5551\/jat.RV17010","volume":"25","author":"M Kurano","year":"2018","unstructured":"Kurano M, Yatomi Y. Sphingosine 1-phosphate and atherosclerosis. J Atheroscler Thromb. 2018;25:16\u201326.","journal-title":"J Atheroscler Thromb"},{"key":"2624_CR56","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/s41467-023-38069-5","volume":"14","author":"A Polzin","year":"2023","unstructured":"Polzin A, Dannenberg L, Benkhoff M, Barcik M, Helten C, Mourikis P, Ahlbrecht S, Wildeis L, Ziese J, Zikeli D, Metzen D, Hu H, Baensch L, Schr\u00f6der NH, Keul P, Weske S, Wollnitzke P, Duse D, Saffak S, Cramer M, B\u00f6nner F, M\u00fcller T, Gr\u00e4ler MH, Zeus T, Kelm M, Levkau B. Revealing concealed cardioprotection by platelet Mfsd2b-released S1P in human and murine myocardial infarction. Nat Commun. 2023;14:2404.","journal-title":"Nat Commun"},{"key":"2624_CR57","doi-asserted-by":"publisher","first-page":"294","DOI":"10.5551\/jat.RV17020","volume":"25","author":"A Shioi","year":"2018","unstructured":"Shioi A, Ikari Y. Plaque calcification during atherosclerosis progression and regression. J Atheroscler Thromb. 2018;25:294\u2013303.","journal-title":"J Atheroscler Thromb"},{"key":"2624_CR58","doi-asserted-by":"publisher","first-page":"e74341","DOI":"10.1371\/journal.pone.0074341","volume":"8","author":"PJ Meikle","year":"2013","unstructured":"Meikle PJ, Wong G, Barlow CK, Weir JM, Greeve MA, MacIntosh GL, Almasy L, Comuzzie AG, Mahaney MC, Kowalczyk A, Haviv I, Grantham N, Magliano DJ, Jowett JBM, Zimmet P, Curran JE, Blangero J, Shaw J. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS ONE. 2013;8:e74341.","journal-title":"PLoS ONE"},{"key":"2624_CR59","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.2337\/dc18-0840","volume":"41","author":"C Razquin","year":"2018","unstructured":"Razquin C, Toledo E, Clish CB, Ruiz-Canela M, Dennis C, Corella D, Papandreou C, Ros E, Estruch R, Guasch-Ferr\u00e9 M, G\u00f3mez-Gracia E, Fit\u00f3 M, Yu E, Lapetra J, Wang D, Romaguera D, Liang L, Alonso-G\u00f3mez A, Deik A, Bullo M, Serra-Majem L, Salas-Salvad\u00f3 J, Hu FB, Mart\u00ednez-Gonz\u00e1lez MA. Plasma lipidomic profiling and risk of type 2 diabetes in the predimed trial. Diabetes Care. 2018;41:2617\u201324.","journal-title":"Diabetes Care"},{"key":"2624_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002395","volume":"9","author":"EH Zobel","year":"2021","unstructured":"Zobel EH, Wretlind A, Ripa RS, Rotbain Curovic V, Von Scholten BJ, Suvitaival T, Hansen TW, Kj\u00e6r A, Legido-Quigley C, Rossing P. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. BMJ Open Diabetes Res Care. 2021;9: e002395.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2624_CR61","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12933-023-01845-0","volume":"22","author":"D Denimal","year":"2023","unstructured":"Denimal D, Bergas V, Pais-de-Barros J-P, Simoneau I, Demizieux L, Passilly-Degrace P, Bouillet B, Petit J-M, Rouland A, Bataille A, Duvillard L, Verg\u00e8s B. Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes. Cardiovasc Diabetol. 2023;22:104.","journal-title":"Cardiovasc Diabetol"},{"key":"2624_CR62","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","volume":"146","author":"N Marx","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146:1882\u201394.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02624-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02624-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02624-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:04:11Z","timestamp":1740157451000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02624-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2624"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02624-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This information is included in the manuscript body.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}